Trials or case series (20 or more patients) reporting outcomes in newly diagnosed PCNSL patients treated with consolidation HDC-ASCT after methotrexate-based initial treatment
| Reference . | N . | Induction regimen . | ORR to induction . | HDC-ASCT regimen . | Received consolidation HDC-ASCT . | Received consolidation WBRT* . | ORR to HDC-ASCT . | Med F/u (mo) . | ITT 3-y PFS . | ITT 3-y OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Regimens including WBRT to all patients | ||||||||||
| 29 | 30 | MTX 8 g/m2, Ara-C, thiotepa | 80% | BCNU, thiotepa + WBRT | 23 (77%) | 21 (70%) | 100% | 63 | na | 69% |
| 33 | 25 | MTX 3 g/m2, BCNU, VP16, methylpred | 84% | BEAM + WBRT | 17 (68%) | 24 (96%) | 100% | 34 | 58% | 64% |
| Regimens with WBRT to patients achieving less than CR | ||||||||||
| 34 | 28 | MTX 8 g/m2 | 61% | Busulfan, thiotepa + WBRT if no CR | 16 (70%) | 8 (29%) | 69% | 15 | 45% | 48% (2 y) |
| Regimens without WBRT | ||||||||||
| 17 | 28 | MTX 3.5 g/m2, Ara-C | 57% | BEAM | 14 (50%) | 0 | 77% | 28 | 25% | 60% |
| This study | 32 | MTX 3.5 g/m2, rituximab, procarbazine, vincristine | 97% | Thiotepa, busulfan, CTX | 26 (81%) | 0 | 92% | 45 | 79% | 81% |
| Reference . | N . | Induction regimen . | ORR to induction . | HDC-ASCT regimen . | Received consolidation HDC-ASCT . | Received consolidation WBRT* . | ORR to HDC-ASCT . | Med F/u (mo) . | ITT 3-y PFS . | ITT 3-y OS . |
|---|---|---|---|---|---|---|---|---|---|---|
| Regimens including WBRT to all patients | ||||||||||
| 29 | 30 | MTX 8 g/m2, Ara-C, thiotepa | 80% | BCNU, thiotepa + WBRT | 23 (77%) | 21 (70%) | 100% | 63 | na | 69% |
| 33 | 25 | MTX 3 g/m2, BCNU, VP16, methylpred | 84% | BEAM + WBRT | 17 (68%) | 24 (96%) | 100% | 34 | 58% | 64% |
| Regimens with WBRT to patients achieving less than CR | ||||||||||
| 34 | 28 | MTX 8 g/m2 | 61% | Busulfan, thiotepa + WBRT if no CR | 16 (70%) | 8 (29%) | 69% | 15 | 45% | 48% (2 y) |
| Regimens without WBRT | ||||||||||
| 17 | 28 | MTX 3.5 g/m2, Ara-C | 57% | BEAM | 14 (50%) | 0 | 77% | 28 | 25% | 60% |
| This study | 32 | MTX 3.5 g/m2, rituximab, procarbazine, vincristine | 97% | Thiotepa, busulfan, CTX | 26 (81%) | 0 | 92% | 45 | 79% | 81% |
Number of patients who received WBRT as part of initial treatment, in the absence of tumor progression.
Ara-C, cytarabine; CTX, cyclophosphamide; Med F/u, median follow-up; methylpred, methylprednisolone; MTX, methotrexate; na, not available; ORR, objective response rate; VP-16, etoposide.